To the Editor:

Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL) is categorized as high risk (HR) with risk factors such as advanced age, elevated WBC count, and high-risk cytogenetic abnormalities. The remaining older adolescents and young adults (AYA, aged 15--39 years) without risk factors are AYA with standard-risk (SR) Ph-ALL and represent a group with lower cumulative incidence of relapse and better overall survival. Allogeneic hematopoietic stem cell transplantation (allo-SCT), especially from human leukocyte antigen (HLA)-matched sibling donors (MSDs) or matched unrelated donors (MUDs), is one of the preferred options over chemotherapy in the consolidation treatment of Ph-ALL \[[@CR1], [@CR2]\]. However, the shortage of MSDs and limited availability of MUDs prevents large populations from benefiting from allo-SCT \[[@CR3]\].

Recently, unmanipulated haploidentical SCT (haplo-SCT) using pretransplant ATG and granulocyte colony-stimulating factor (G-CSF)-stimulated grafts (ATG+G-CSF) or posttransplant cyclophosphamide (PT-CY) protocol was confirmed equivalent to HLA-matched SCT in ALL \[[@CR4]--[@CR6]\]. However, as prospective data is absent, it is unknown whether AYA SR Ph-ALL patients should pursue haplo-SCT instead of consolidation chemotherapy in the absence of MSDs and MUDs \[[@CR7], [@CR8]\]. This multicenter prospective clinical trial was registered at <https://clinicaltrials.gov> as NCT02042690 (Suppl [Method](#MOESM3){ref-type="media"}).

In total, 131 consecutive Ph-ALL young adult patients (YA, aged 18--39 years) without high-risk features who achieved CR1 were enrolled with a median follow-up of 32 months (Figure S[1](#MOESM1){ref-type="media"}, Table S[1](#MOESM2){ref-type="media"}). haplo-SCT was superior to chemotherapy in terms of lower CIR and improved LFS and OS in total enrolled CR1 patients without landmark (Figure S[2](#MOESM1){ref-type="media"}); haplo-SCT was also associated with lower CIR and improved LFS in the subgroup of patients who took only 1 cycle to achieve CR and been MRD negative after Con-1 (Figure S[3](#MOESM1){ref-type="media"}).

Dynamic landmark suggested haplo-SCT was associated with lower CIR and improved LFS and OS compared with chemotherapy between 0 and 12 months post-CR1(Figure S[4](#MOESM1){ref-type="media"}). Then, 6 months was chosen as the fixed landmark point, relapse or NRM before 6 months post-CR1 (*n* = 15) was excluded, those undergoing SCT after the landmark were included in the chemotherapy group, and the remaining patients (*n* = 99) were divided into the haplo-SCT group (*n* = 49) and chemotherapy group (*n* = 50) (Table S[2](#MOESM2){ref-type="media"}). In landmark analysis, CIR (2-year CIR 12.8%, 95% CI 3.2--22.4 vs 46.7%, 95% CI 30.5--52.9%; *P* = 0.0017), LFS (2-year LFS 80.9%, 95% CI 66.4--89.6 vs 51.1%, 95% CI 34.2--65.6%; *P* = 0.0116), and OS (2-year OS 91.2%, 95% CI 78.2--96.6% vs 75.7%, 95% CI 64.8--93.2%; *P* = 0.0408) continued to be better in the haplo-SCT group than in the chemotherapy group (Fig. [1](#Fig1){ref-type="fig"}a, c, d), while NRM was comparable (Fig. [1b](#Fig1){ref-type="fig"}). Fig. 1Comparison between chemotherapy and haplo-SCT with landmark. **a** Cumulative incidence of relapse (CIR). **b** Non-relapse mortality (NRM). **c** Leukemia-free survival (LFS). **d** Overall survival (OS)

Cox PH regression model was constructed considering the time of haplo-SCT as a time-dependent exposure based on PH test (Table S[3](#MOESM2){ref-type="media"}). Univariate analysis for CIR, NRM, LFS, and OS was listed in Table S[4](#MOESM2){ref-type="media"}. Both crude- and PS-adjusted multivariate analyses suggested haplo-SCT was associated with lower CIR (PS-adjusted HR 0.195, 95% CI 0.076--0.499, *P* = 0.001) and improved LFS (PS-adjusted HR 0.297, 95% CI 0.131--0.675, *P* = 0.003) and OS (HR 0.346, 95% CI 0.140--0.853, *P* = 0.011) compared with chemotherapy. Con1 FCM MRD (+ vs −) was an independent risk factor for CIR (PS-adjusted HR 3.609, 95% CI 1.562--8.340, *P* = 0.006) and LFS (PS-adjusted HR 2.825, 95% CI 1.298--6.152, *P* = 0.009). Diagnosis (T vs B; HR 2.564, 95% CI 1.361--4.823, *P* = 0.014) was an independent risk factor for OS. No independent risk factors identified for NRM. When stratified by Con-1 MRD and diagnosis, haplo-SCT decreased CIR in all subgroups (Con-1 MRD+ vs MRD−, B-ALL vs T-ALL) while improved LFS and OS only in the Con-1 MRD+ and B-ALL subgroups but not in the Con-1 MRD− and T-ALL subgroups (Table S[5](#MOESM2){ref-type="media"}, Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Forest plot of time-dependent multivariable Cox regression model. **a** Cumulative incidence of relapse (CIR). **b** Non-relapse mortality (NRM). **c** Leukemia-free survival (LFS). **d** Overall survival (OS)

Currently, haplo-SCT is only an optional rather than a preferred choice for postremission therapy compared with MSD or 10/10 MUD-SCT MSD-SCT is the preferred treatment for ALL, and MUD is also acceptable in most countries \[[@CR7]\]. This study presents the first prospective assessment related to the controversial issue whether YA patients with SR ALL benefit more from haplo-SCT than adult chemotherapy regimen. The advantages of a low CIR and an acceptable NRM resulted in promising results of haplo-SCT in the present study, which were comparable to those in previous reports (5-year LFS 68.7%, OS 70.1%) \[[@CR5], [@CR8]\]. As NRM of haplo-SCT has generally improved with either the PT-CY (7 to 23%) or ATG+G-CSF protocol (11--13%) compared with early procedures \[[@CR4], [@CR9], [@CR10]\], NRM might no longer be a limiting factor of receiving haplo-SCT, especially in experienced centers. haplo-SCT was associated with lower CIR in both the Con-1 MRD +/− subgroups in the current study; meanwhile, cautions must be taken as CIR of non-SCT cohort might be higher compared with previous reports (46--49%) \[[@CR1], [@CR2]\]. More recently, some studies suggested pediatric-inspired regimens might further decrease the CIR to 12--33% and result encouraging survival (3--5 years LFS 59--73%, OS 60--79%) compared with adult regimen \[[@CR11]\], while some reported similar outcomes \[[@CR12]\]. Currently, guidelines tried to recommend the regimens both by adult and pediatric settings as adult regimens were still widely used, especially in developing countries \[[@CR13], [@CR14]\]. In addition, blinatumomab, which might further decrease CIR in MRD+ALL \[[@CR15]\], was not available in the current study. Therefore, it remained to be addressed the role of haplo-SCT in the era of pediatric-inspired regimens and blinatumomab in the future.

The present study might be one of the best available evidence to compare haplo-SCT and adult chemotherapy for YA SR Ph-ALL in CR1. Cautions must be taken in interpreting these results due to non-randomized design and a relatively small group of patients. haplo-SCT might become one of the preferred therapies for YA patients with SR Ph-ALL in the absence of MSD or MUD-SCT.
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